ARS Pharmaceuticals Plans to Sue Lupin Inc. for Patent Infringement on Adrenaline Nasal Spray Generic Drug

Summary

ARS Pharmaceuticals Inc. announced on August 13, 2025, that it received a Paragraph IV notice from Lupin Inc., which has submitted an ANDA to the FDA for a generic version of Neffy©2 mg (epinephrine nasal spray). This application seeks approval before the expiration of several U.S. patents listed in the Orange Book. ARS Pharmaceuticals plans to defend its patents vigorously and intends to file a patent infringement lawsuit against Lupin.Reuters

Impact Analysis

First-Order Effects: ARS Pharmaceuticals’ decision to file a patent infringement lawsuit could protect its market share for Neffy©2 mg by potentially delaying or preventing generic competition from Lupin. Successfully defending its patents could uphold its pricing power and revenue streams from this product. However, the litigation process can be costly and time-consuming, affecting ARS’s financials and investor sentiment.Reuters Second-Order Effects: The outcome of this litigation could impact the generic pharmaceutical industry by setting precedents for patent challenges and defenses. It may also influence the strategies of other companies considering similar generic applications or those holding similar patents.QQ News Investment Opportunities: Investors in ARS Pharmaceuticals may consider options strategies to hedge against potential volatility in the stock price due to uncertainty in litigation outcomes. Additionally, monitoring Lupin’s stock for price movements related to the lawsuit could provide trading opportunities.Reuters